

Presentation Material

Financial Results for the Fiscal Year
Ended July31,2025

StemRIM Inc.(Stock code:TSE4599)

Masatsune OKAJIMA, President & Chief Executive Officer
September 12,2025



Agenda

1

Company Overview

- Corporate Mission
- Mode of Action of “Regeneration-Inducing Medicine™”
- Business Model
- Management Indicators

2

Progress in Research and Development

- Highlights for the Fiscal Year Ended July 31, 2025

3

Summary of Activities the Fiscal Year Ended July 31,2025

- Financial Summary
- IP Strategy
- Business Development Activities

1. Company Overview

Overcoming Refractory Diseases by “Regeneration-Inducing Medicine™”



Stem cell Regeneration-Inducing Medicine



StemRIM is a biotech company aiming to develop “Regeneration-Inducing Medicine™” a next generation of regenerative medicine.

“Regeneration-Inducing Medicine™” is new class of medicine that induces functional regeneration of damaged tissues or organs by maximizing the patient's innate ability of tissue repairing.

We aim for a future in which “Regeneration-Inducing Medicine™” helps patients all over the world suffering from refractory diseases.


Mode of Action of “Regeneration-Inducing Medicine™”

Bone marrow mesenchymal stem cells mobilized into the peripheral blood stream induce the tissue regeneration.



Business Model

A business model that generates income by licensing out product development, manufacturing, and marketing rights to pharmaceutical companies in Japan and overseas.



Our Management Indicators

Annual Research and Development Expenses

1.39 billion yen

(One-year period from August 2024 to July 2025)

Cash Burn Rate for Month

117 million yen

(Results for the Fiscal Year Ended July 2025)

Sufficient funds secured for research and development activities until 2028.

Cash and Deposits

6.9 billion yen

(As of the end of July 2025)

Number of Clinical Development Pipelines

5

Clinical trials have been initiated in patients for epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, chronic liver disease, and osteoarthritis.

2. Progress in Research and Development

The background is a solid blue color. On the right side, there is a faint, abstract graphic. It consists of a series of overlapping circles of varying sizes, some of which are filled with a grid pattern. To the right of these circles, there is a network diagram with several nodes (small dots) connected by thin lines, suggesting a molecular structure or a data network.

Highlights for the Fiscal Year Ended July 31 2025

I .

**Redasemtide: Global Phase 2b Trial for Acute Ischemic Stroke /
Changes to Clinical Trial Protocols**

II .

**Redasemtide: Additional Phase 2 Trial for Dystrophic Epidermolysis Bullosa /
Last Patient In**

III .

Reorganizing our Development Pipelines

Redasemtide: Global Phase 2b Trial for AIS

I .

April 2019:

Initiation of Phase 2 corporate-sponsored clinical trial (In Japan)

October 2021:

Completion of Phase 2 corporate-sponsored clinical trial (In Japan)

April 2023:

Initiation of global Phase 2b clinical trial

February 2025:

Amendment to the global Phase 2b clinical trial protocol


April 2025:

Interim analysis of the global Phase 2b clinical trial

Background to the Clinical Trial Plan Change

- Advances in endovascular recanalization therapy have changed the treatment system
- Considering adding a cohort of patients who underwent endovascular recanalization therapy to respond to a wide range of patient groups
- Conduct an interim analysis and perform a “Futility Analysis” of the existing cohort.

I. Redasemtide: Global Phase 2b Trial for AIS



1. Addition of Clinical Trial Subjects and Case Numbers

Due to Changes in the Stroke Treatment Paradigm, a new patient group that underwent thrombolytic therapy and mechanical thrombectomy has been added. As a result, the number of enrolled cases in the clinical trial has increased.

*jCRT:2031230083

2. Reduction in the Number of Cases Due to Discontinuation of Dose 2


For acute ischemic stroke patients ineligible for endovascular recanalization therapy, futility analysis was conducted, and based on the results, dose 2 was discontinued.

Relaxation of patient inclusion criteria, increased trial patient population, and efficient patient enrollment following discontinuation of Dose 2 are expected to prevent a significant extension of the trial period.

I. Redasemtide: Global Phase 2b Trial for AIS

Phase 2b Trial Protocol (After interim analysis)

Study objectives	Evaluation of the Efficacy, Safety, and Tolerability of Redasemtide in Patients with Acute Ischemic Stroke
Subject population	Patients aged 18 years or older who can receive treatment within 25 hours of stroke onset, with a baseline NIHSS* score between 8 and 22.
Study design	Multicenter, Randomized, Placebo-Controlled, Double-Blind
Intervention	Cohort A: Patients Who Did Not Received Thrombolytic Therapy and/or Mechanical Thrombectomy • Redasemtide (1.5 mg/kg) treatment group • Placebo group Cohort B: Patients Who Receive Thrombolytic Therapy or Mechanical Thrombectomy • Redasemtide (1.5 mg/kg) treatment group • Placebo group Total: 679 subjects
Dose	Intravenous Administration Once Daily for 90 Minutes Over 5 Days
Primary End Point	Modified Rankin Scale (mRS) at 90 Days After Initial Dosing
Region	Japan, Europe, North America, China, etc.



Future Outlook

Planned Market Launch by
April 2028 ~ March 2031

*NIHSS(National Institutes of Health Stroke Scale): Stroke Neurological Severity Rating Scale (42 points in total, the higher the score, the more severe)

II. Redasemtide: Additional Phase 2 Trial for DEB

Additional Phase 2 Protocol	
Study objectives	Evaluation of efficacy and safety of Redasemtide in patients with dystrophic epidermolysis bullosa having intractable ulcers
Study design	Single arm, multicenter, open label, uncontrolled
Intervention	Redasemtide (1.0 mg/kg) group: More than 3 participants
Regimen	30-minute intravenous infusion once a day, total 10 times/4 weeks [1st week of administration: 4 times/week, 2nd-4th weeks of administration: twice/week (once every 3-4 days)]
Primary endpoint	Closure of intractable ulcer

Clinical Trial Timeline to Date

December 2017: Initiation of Phase 2 investigator-initiated clinical trial
September 2019: Completion of Phase 2 investigator-initiated clinical trial


March 2020: Completion of follow-up study for Phase 2 investigator-initiated clinical trial

July 2022: Initiation of additional Phase 2 clinical trial

March 2023: First patient enrolled in the additional Phase 2 clinical trial

May 2023: Orphan Drug Designation

July 2025: Final patient enrolled in the additional Phase 2 clinical trial



In May 2023, the Ministry of Health, Labour and Welfare designated ledasemtide as an orphan drug for hypoparathyroidism-related epidermolysis bullosa. This designation reflects the Ministry's recognition of the development plan's validity for treating hypoparathyroidism-related epidermolysis bullosa. Eligibility for the priority review system is expected to shorten the review period, facilitating earlier approval.

Status

Planned Market Launch by March 2028

* Shionogi & Co. Ltd., 1st Quarter of Fiscal 2025 Financial Results, July 28, 2025, pp.31

** jRCT2031220378

III. Reorganizing our Development Pipelines

Reorganization of pipeline development codes aimed at the optimal allocation of R&D resources.

Development Pipeline (Revised)

Project code	Indication	Status	Investigator
Redasemtide/TRIM2 (HMGB1 cell mobilization domain peptides)	Epidermolysis Bullosa	 Additional P2	Shionogi & Co., Ltd.
	Acute Ischemic Stroke	 Global P2b	Shionogi & Co., Ltd.
	Ischemic Cardiomyopathy	 Physician-Initiated P2	Osaka University
	Osteoarthritis of the knee	 Physician-Initiated P2	Hirosaki University
	Chronic liver disease	 Physician-Initiated P2	Niigata University
TRIM3 (Novel Regeneration-Inducing peptide for Systemic administration)	(Not disclosed)	—	In-house (partnership is planned)
TRIM4 (Novel Regeneration-Inducing peptide for Systemic administration)	(Not disclosed)	—	In-house (partnership is planned)
TRIM5 (Novel Regeneration-Inducing peptide for Local administration)	(Not disclosed)	—	In-house (Expansion of animal model data)
SR-GT1 (Stem cell gene therapy)	Epidermolysis Bullosa	—	In-house (partnership is planned)

Development Pipeline (Before Revision)

Project code	Development candidate	Indication
PJ1	Redasemtide (HMGB1 cell mobilization domain peptides)	Epidermolysis Bullosa
		Acute Ischemic Stroke
		Ischemic Cardiomyopathy
		Osteoarthritis of the knee
		Chronic liver disease
PJ2	-01 Novel Regeneration-Inducing peptide for Systemic administration (TRIM3)	Not disclosed
	-02 Novel Regeneration-Inducing peptide for Systemic administration (TRIM4)	Not disclosed
PJ3	Novel Regeneration-Inducing peptide for Local administration (TRIM5)	Not disclosed
PJ4	Autologous cell collection device for treatment	Multiple tissue damage diseases
PJ5	Stem cell gene therapy (SR-GT1)	Epidermolysis Bullosa



3. Summary of Activities the Fiscal Year Ended July 2025

Summary of Financial Results

- For FY 2025, there were no recognition of milestone revenues related to research progress or upfront payments from contracts. As a result, **operating revenue was none**. Since we are a drug discovery bio-venture, we have an unstable revenue structure considering our business model.
- As of the end of FY 2025, we hold **6,994 million yen** in cash and deposits.
The estimated annual expenditure for the FY 2025 is between 1,530 million yen and 2,010 million yen (cash outflows related to R&D: 1,300 million yen to 1,700 million yen, cash outflows for general administrative expenses: 230 million to 310 million yen). At present, **we have secured sufficient funds to sustain stable R&D activities until 2028**.

(Millions of yen)


	FY 2021.7	FY 2022.7	FY 2023.7	FY 2024.7	FY 2025.7	Function (FY on FY)
Operating revenue	1,400	22	2,350	—	—	—
R&D expenses	1,523	1,421	1,567	1,453	1,394	-57
Total operating expenses	1,993	2,003	2,207	2,076	1,971	-104
Operating Income (loss)	(593)	(1,980)	142	(2,076)	(1,971)	+104
Ordinary Income (loss)	(583)	(1,972)	145	(2,077)	(1,970)	+107
Net Income (loss)	(582)	(1,948)	168	(2,022)	(1,929)	+92
Cash and deposit	10,172	8,880	10,217	8,410	6,994	

IP Strategy

Patents related to “Regeneration-Inducing Medicine”™ have been granted in various countries. We are steadily promoting the intellectual property protection of our research outcomes, paving the way for global expansion.

Total Patents **134**
Patent Pending **83**

Patent Grant Status




Countries of Grant and Application



* As of July 2025

TRIM3, TRIM4

We have identified several peptides that mobilize mesenchymal stem cells from the bone marrow into the bloodstream, accumulate in damaged tissues, and induce functional regeneration. Among them, two peptides with particularly prominent activity have been selected as candidates for the next-generation “Regeneration-Inducing Medicine™” : TRIM3 and TRIM4, and out-licensing activities have been initiated.



Business Development

Continuing from last year, out-licensing negotiations were conducted with multiple pharmaceutical companies both domestically and internationally.



2024.10.9~11
@ Yokohama, JPN



J.P.Morgan
Healthcare Conference

2025.1.13~16
@ San Francisco, CA



Bio International
Convention

2025.6.15~6.21
@ Boston, MA




4. Appendix



Discovery of in-vivo mechanism inducing tissue regeneration

Discovery of crosstalk mechanism between damaged skin and bone marrow mesenchymal stem cells via necrotic tissue-derived factor




References:
J Immunol. 2015 Feb 15; 194(4):1996-2003
Proc Natl Acad Sci U S A. 2011 Apr 19; 108(16):6609-14.

Discovery of in-vivo mechanism inducing tissue regeneration


• Differences between normal skin and epidermolysis bullosa skin

In normal skin (Figure A), type 7 collagen functions like an adhesive, bonding the epidermis and dermis, the superficial layers of skin. In epidermolysis bullosa congenita (Figure B), the epidermis and dermis are easily detached with the slightest irritation due to abnormal type 7 collagen. Since epidermal stem cells, which are responsible for supplying epidermal cells, reside in the epidermis, the epidermal stem cells are lost from the skin of patients with epidermolysis bullosa, and the epidermis loses its regenerative capacity.




Discovery of in-vivo mechanism inducing tissue regeneration

The beginning of the research and development on “Regeneration-Inducing Medicine™” :
Hypothesis of stem cell recruitment mechanism from bone marrow to damaged skin.



Possible replenishment of stem cells
via the bloodstream




Hypothesis of stem cell
recruitment mechanism via
blood flow

References :
“Igaku-no-ayumi” Vol.265 No.5 463-468; 2018
Skin Diseases :41(1); 7-12,2019
Photo courtesy of Osaka University

HMGB1 peptide drugs with improved safety

Designing highly safe, chemically synthesized peptide drug from A-Box domain of HMGB1 protein



Prof. Katsuto Tamai
Osaka University



Identifying the function of
protein domains


A box

Bone marrow mesenchymal stem cell activating domain, named "KOI2-domain"


B box

Innate immune response-activating domain that induces inflammation

References:
J Intern Med. 2004
Mar ; 255(3):351-66.




Advantages of “Regeneration-Inducing Medicine™”



Advantages of “Regeneration-Inducing Medicine™”


Ectodermal mesenchymal stem cells have high pluripotency and differentiation ability to various tissues.



Expanding Indications and Markets(Number of patients)

Targeting all areas where mesenchymal stem cell therapy can be effective

 : Clinical trial on going




Functions of mesenchymal stem cells

In-vivo mesenchymal stem cells have 5 distinctive capabilities


1. Cell migration ability

Mesenchymal stem cells migrate to damaged tissue via the bloodstream



2. Immunomodulatory ability


Modulates immune response and inhibits the spread of tissue damage caused by excessive inflammation



* MMP: Matrix metalloproteases


3. Trophic factor secretion ability

Promotes cell proliferation and tissue repair by secreting growth factors and cytokines to cells in damaged tissue




4. Fibrosis regulation ability

Regulates and inhibits excessive fibrosis of damaged tissue




5. Tissue regeneration ability



In vitro culture reduces the functions of MSCs

“Regeneration-Inducing Medicine™” can avoid functional degradation of mesenchymal stem cells due to in vitro culture

Manufacturing process of conventional cellular medicine



Mesenchymal stem cells lose their functions during in vitro culture


Source: Stem Cell Research & Therapy 2018,9:131



“The effects of MSC cell therapy are limited to inflammation suppression and supply of growth factors to the remaining cells”, reported by Caplan AI

「Mesenchymal Stem Cells: Time to Change the Name!」 Arnold Caplan June 2017

Induction of MSC in “Regeneration-Inducing Medicine™”



Induction of mesenchymal stem cells into damaged tissues while retaining their native functions



Source: Stem Cells Transl Med. 2017 Jun; 6(6):1445-1451. doi: 10.1002/sctm.17-0051. Epub 2017 Apr 28.


Summary of advantages of “Regeneration-Inducing Medicine™”

“Regeneration-Inducing Medicine™” includes advantages in both cell therapy and chemicals

		“Regeneration-Inducing Medicine™”	Cell therapy	Chemicals
Efficacy	<u>Tissue regeneration</u>	 Applicable for large-scale tissue damage	 Applicable for large tissue damage with large number of cells	 No regeneration
	<u>Mechanism of action</u>	 Use in vivo native regeneration mechanism	 Cellular physiological activity	 Targeting molecules often including side-effect and off-target
	<u>Indications</u>	 Same compound can cover a wide range of indications	 Same platform can cover a wide range of indications	 In general, targeting limited indications caused by same mechanism
Safety	<u>Noninvasive</u>	 Compound mobilizes the patient's cells in vivo and no rejection	 Invasive in cell collection Immune-rejection in allogenic case	 Low noninvasive
Quality	<u>Quality control</u>	 Easy quality control and stable production	 Cell culture includes risk of cellular change	 Easy quality control and stable production
Other benefit	<u>Cost</u>	 Normal industrial drug production	 CPC and cell collection and transplantation facility is required	 Affordable and large-scale production
	<u>Regulatory affairs</u>	 Same as general compound drugs	 No standard, and case-by-case regulation is required	 Standardized regulation

Summary of advantages of “Regeneration-Inducing Medicine™”

“Regeneration-Inducing Medicine™” can solve the four major problems of conventional cell therapy



Activities of “StemRIM Institute of Regeneration-Inducing Medicine, Osaka University”



StemRIM

StemRIM Institute of
Regeneration-Inducing Medicine

In June 2020, StemRIM Institute of Regeneration-Inducing Medicine, Osaka University (covering an area of 1,540 square meters) was established on the 6th and 7th floors of the Techno Alliance Building at Osaka University's Suita Campus. Professor Masayuki Endo (Department of Children's and Women's Health, Graduate School of medicine and Division of Health Sciences, Osaka University) was appointed as the institute's director. The team includes distinguished members such as Specially Appointed Professor Shinya Murakami (Department of Periodontology and Regenerative Dentistry, Osaka University, Graduate School of Dentistry.), Professor Masaru Ishii (Department of Immunology and Cell Biology, Graduate School of medicine and Frontier Biosciences, Osaka University), and Professor Manabu Fujimoto (Department of Integrated Medicine, Graduate School of medicine, Osaka University). Together, they aim to explore and advance the multi-faceted development of “Regeneration-Inducing Medicine”TM. To date, several collaborative research projects have made significant progress.

Joint Research Projects

	(number of events)						
	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY on FY	Notes
Division of Health Sciences	1	2	3	2	2	±0	Neonatal-Associated Diseases
Division of Biofunctional Research	—	—	—	—	—	±0	
Division of Medical Research	—	1	2	2	3	+1	Nervous System Diseases, Orthopedic-Related Diseases
Division of Dentistry	3	5	5	5	6	+1	Periodontitis-Related Diseases
Total	4	8	10	9	11	+2	



Website (Japanese):

<https://stemrim-osaka-u.jp/>



Corporate Information

■ Corporate Name	StemRIM Inc.
■ Chief Executives	Masatsune Okajima (Representative Director)
■ Established	October 30, 2006
■ Business Description	Research and Development of “Regeneration Inducing-Medicine™”
■ Shareholders' Equity	5,861 million yen
■ Equity Ratio	77.9 %
■ Number of Employees	69

■ **Head Office**

7-7-15, Saito-Asagi, Ibaraki-City,
Osaka, Japan




■ **StemRIM Institute of Regeneration-Inducing Medicine, Osaka University**

Techno-Alliance Building, 2-8,
Yamadaoka, Suita-City, Osaka, Japan



■ **Endowed Chair for Regeneration-Inducing Medicine/ Joint Research Course in Stem Cell and Gene Therapy**

The Center of Medical Innovation and
Translational Research, 2-2, Yamadaoka,
Suita-City, Osaka, Japan



As of the End of January 2025

StemRIM Management

Masatsune Okajima, President and CEO

President and CEO, StemRIM Inc. (Oct. 2023 – Present)
President, StemRIM Inc. (March 2019 – Oct. 2023)
Vice president, Medicinova Inc. (Sep. 2006 – March 2019)
Deputy General Manager, Daiwa Securities SMBC Co., Ltd. (April 2002 – Aug. 2006)
Manager, Daiwa Securities SB Capital Markets Co., Ltd. (currently Daiwa Securities SMBC Co., Ltd.) (April 1999 – March 2002)
Sumitomo Capital Securities Co., Ltd. (Oct. 1996 – April 1999)
Sumitomo Bank, Ltd. (currently Mitsui Sumitomo Bank) (April 1991 – Oct. 1996)

Katsuto Tamai, Founder, Director and CSO

Director, StemRIM Inc. (Oct. 2022 – Present)
Guest Professor, Endowed course of Regeneration-Inducing Medicine Graduate School of Medicine/ Faculty of Medicine, Osaka University (Oct. 2023 – Present)
Professor, Endowed course of Regeneration-Inducing Medicine Graduate School of Medicine/ Faculty of Medicine, Osaka University (Oct. 2010 – Sep. 2023)
Director, StemRIM Inc. (Feb. 2007 – Aug. 2010)
Associate professor, Department of Gene Therapy, Graduate School of Medicine/ Faculty of Medicine, Osaka University (May 2003 – Sep. 2009)

Noriko Sawai, External director

Head of healthcare team, Social Innovation and Investment Foundation (Aug. 2022 – present)
Impact Officer,
Social Innovation and Investment Foundation (Feb. 2020 – July 2022)
External director, StemRIM Inc. (Oct. 2019 – Present)
DeNA Co. (June 2014 – Jan. 2020)
CSK Venture Capital Co. (April 1995 – May 2014)

Hirotsada Nagai, External director

President, HyakusanSoken KK (July 2022 - Present)
External directors, StemRIM Inc. (Oct. 2020 - Present)
Auditor, Regional Fish Institute, Ltd. (May 2020 – Present)
Director, PRDM Co., Ltd. (March 2018 – Present)
Director, PorMedTec Co., Ltd. (Dec. 2017 – Present)
Director, Kyoya KK (Dec. 2017 - Present)
Pharmaceuticals and Medical Devices Agency (PMDA) (Sep. 2012 – July 2014)
Pharmaceutical and Food Safety Bureau of Ministry of Health, Labour and Welfare (April 2001 – Sep. 2017)

Yoji Kudo, External audit

Akihiro Mizukami, External audit

Yoichiro Shimada, External audit

Disclaimer

This document is based on economic, regulatory, market, and other conditions as of its publication date, and neither the company nor its representatives guarantee the accuracy or completeness of the information contained herein. The information may change without prior notice, and such changes could be significant.

Additionally, any statements in this document regarding future forecasts are based on the company's current assumptions and judgments, considering information currently available. These include known and unknown risks, uncertainties, and other factors. Such risks and uncertainties could cause actual performance or financial conditions to differ significantly from the future performance or financial conditions indicated or implied in these forward-looking statements.

Information related to companies or parties other than the company, or information created by them, is based on generally available information and other sources referenced herein. The company has not independently verified the accuracy or appropriateness of such information and makes no guarantees regarding it.

This document is intended solely to disclose information about the company and is not intended as investment advice. Please make any investment decisions regarding the company's securities at your discretion. Additionally, the company and information providers are not liable for any damages arising from actions taken based on this document.

This document and its contents may not be disclosed or used without prior written consent from the company.